WuXi Biologics, a global open-access biologics technology platform company, announced that the construction of new biologics drug substance manufacturing facility has commenced on the Industrial Development Authority’s (IDA) greenfield site in Mullagharlin, Dundalk, Co. Louth in Ireland. It’s the company’s first site outside of China and is supported by the Irish government through IDA Ireland. The facility is designed to run both…
Chinese Drugmaker to Expand Production of Polysaccharides and Enzyme Drugs
Mesa Biotech Opens Manufacturing Facility to Meet Flu Diagnosis Needs
AGC to Acquire Synthetic Pharmaceutical Active Ingredient Manufacturing Plant in Spain
AGC Inc., a manufacturer of glass, chemicals, and high-tech materials, has entered into an agreement with Boehringer Ingelheim to acquire Malgrat Pharma Chemicals S.L.U. (MPC), a subsidiary of Boehringer Ingelheim that manufactures synthetic pharmaceutical active ingredients for the group. By acquiring MPC, AGC will have its first FDA-registered site in Europe in the synthetic pharmaceutical CDMO business. The deal…
Catalent Expands Clinical Packaging Capabilities in Shanghai
GE Healthcare to Open Biotechnology Manufacturing Center in U.K.
GE Healthcare plans to open a biotechnology manufacturing center at the Stevenage Bioscience Catalyst (SBC) Open Innovation Campus, in Stevenage, U.K. In the first half of 2019, the center will start producing a fiber-based purification platform, which has the potential to improve efficiency in the purification steps of manufacturing biopharmaceuticals, gene therapies, and viral vectors. The fiber-based purification…
Cambrex to Acquire Avista Pharma Solutions
Cambrex Corporation, a manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, has entered into a definitive agreement to acquire Avista Pharma Solutions, a contract development, manufacturing, and testing organization, for approximately $252 million. With this acquisition, Cambrex will enter the large and growing market for early stage small molecule…
Alvotech and Fuji Pharma Enter into Exclusive Partnership for Development and Commercialization of Biosimilars in Japan
Alvotech and Fuji Pharma are entering into an exclusive partnership for the commercialization by Fuji Pharma of Alvotech’s biosimilar portfolio in Japan. Under the partnership, Alvotech will be responsible for development and supply of multiple high value biosimilar assets from its current product pipeline, while Fuji Pharma will be responsible for registration and commercialization of…
Lonza and Sartorius Modify Relationship for Supply of Cell Culture Media
Lonza and Sartorius Stedim Biotech (Sartorius) have modified their current agreement for supply of cell culture media by mutual accord. The agreement, signed in 2012, gave Sartorius exclusive sales and marketing rights for certain media and buffers developed and manufactured by Lonza for use in biopharmaceutical manufacturing processes. Lonza retained sales for research-based products, among…
CASI Pharmaceuticals to Build GMP Manufacturing Site in Wuxi, China
CASI Pharmaceuticals, Inc., a U.S.-based biopharmaceutical company providing pharmaceutical products and therapeutics to patients in China and throughout the world, has entered into framework agreements to build a manufacturing site strategically located in the Wuxi Huishan Economic Development Zone in Jiangsu Province, China. The Wuxi development zone is a leading science and technology innovation center…